Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
BackgroundPersistence with antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) is crucial for long-term outcomes. However, real-world data regarding treatment persistence patterns in IPF are scarce.MethodsWe conducted a post hoc analysis of two retrospective, real-world, mu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1586197/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850233311265292288 |
|---|---|
| author | Sebastian Majewski Katarzyna Górska Katarzyna B. Lewandowska Magdalena M. Martusewicz-Boros Małgorzata Sobiecka Wojciech J. Piotrowski |
| author_facet | Sebastian Majewski Katarzyna Górska Katarzyna B. Lewandowska Magdalena M. Martusewicz-Boros Małgorzata Sobiecka Wojciech J. Piotrowski |
| author_sort | Sebastian Majewski |
| collection | DOAJ |
| description | BackgroundPersistence with antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) is crucial for long-term outcomes. However, real-world data regarding treatment persistence patterns in IPF are scarce.MethodsWe conducted a post hoc analysis of two retrospective, real-world, multicenter observational studies (PolExPIR and PolExNIB) that collected clinical data on Polish patients with IPF managed at specialized centers between January 2017 and October 2021. We compared clinical variables between groups of patients who continued and discontinued antifibrotics and evaluated predictive factors for treatment discontinuation.ResultsOverall, 808 patients were included in the analysis. Of these, 278 subjects (34.4%) discontinued therapy over a median follow-up of 16 (8–24) months. The proportion of patients discontinuing therapy was comparable between pirfenidone and nintedanib (37.5% vs. 32.5% respectively; p = 0.15). Additionally, no statistical difference was observed between antifibrotic agents in the distribution of time until treatment discontinuation (log-rank test, p = 0.3). Predictive factors associated with the probability of treatment discontinuation included age (hazard ratio [HR] 1.04; 95% confidence interval [CI] 1.02–1.05), body mass index (BMI, HR 0.97; 95% CI 0.94–0.99), transfer factor of the lung for carbon monoxide (TLco)% predicted (HR 0.98, 95% CI 0.97–0.99), Gender-Age-Physiology (GAP) index score (HR 1.3, 95% CI 1.18–1.42), use of long-term oxygen therapy (LTOT) (HR = 1.7, 95% CI 1.28–2.27) and intermittent dosing adjustment (HR 1.66, 95% CI 1.29–2.15).ConclusionIn this large population-based cohort of patients with IPF, around one-third discontinued antifibrotics during a study follow-up with no difference in the rates and time to discontinuation between pirfenidone and nintedanib. Clinical predictive factors including age, BMI, TLco% predicted, GAP index score, use of LTOT and intermittent dosing adjustment were associated with the risk of treatment discontinuation. |
| format | Article |
| id | doaj-art-d32789e865d04474a8f65db4e6f87bde |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-d32789e865d04474a8f65db4e6f87bde2025-08-20T02:02:57ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-06-011610.3389/fphar.2025.15861971586197Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in PolandSebastian Majewski0Katarzyna Górska1Katarzyna B. Lewandowska2Magdalena M. Martusewicz-Boros3Małgorzata Sobiecka4Wojciech J. Piotrowski5Department of Pneumology, Medical University of Lodz, Lodz, PolandDepartment of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw, PolandFirst Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warsaw, PolandThird Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, PolandFirst Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warsaw, PolandDepartment of Pneumology, Medical University of Lodz, Lodz, PolandBackgroundPersistence with antifibrotic medications in patients with idiopathic pulmonary fibrosis (IPF) is crucial for long-term outcomes. However, real-world data regarding treatment persistence patterns in IPF are scarce.MethodsWe conducted a post hoc analysis of two retrospective, real-world, multicenter observational studies (PolExPIR and PolExNIB) that collected clinical data on Polish patients with IPF managed at specialized centers between January 2017 and October 2021. We compared clinical variables between groups of patients who continued and discontinued antifibrotics and evaluated predictive factors for treatment discontinuation.ResultsOverall, 808 patients were included in the analysis. Of these, 278 subjects (34.4%) discontinued therapy over a median follow-up of 16 (8–24) months. The proportion of patients discontinuing therapy was comparable between pirfenidone and nintedanib (37.5% vs. 32.5% respectively; p = 0.15). Additionally, no statistical difference was observed between antifibrotic agents in the distribution of time until treatment discontinuation (log-rank test, p = 0.3). Predictive factors associated with the probability of treatment discontinuation included age (hazard ratio [HR] 1.04; 95% confidence interval [CI] 1.02–1.05), body mass index (BMI, HR 0.97; 95% CI 0.94–0.99), transfer factor of the lung for carbon monoxide (TLco)% predicted (HR 0.98, 95% CI 0.97–0.99), Gender-Age-Physiology (GAP) index score (HR 1.3, 95% CI 1.18–1.42), use of long-term oxygen therapy (LTOT) (HR = 1.7, 95% CI 1.28–2.27) and intermittent dosing adjustment (HR 1.66, 95% CI 1.29–2.15).ConclusionIn this large population-based cohort of patients with IPF, around one-third discontinued antifibrotics during a study follow-up with no difference in the rates and time to discontinuation between pirfenidone and nintedanib. Clinical predictive factors including age, BMI, TLco% predicted, GAP index score, use of LTOT and intermittent dosing adjustment were associated with the risk of treatment discontinuation.https://www.frontiersin.org/articles/10.3389/fphar.2025.1586197/fullidiopathic pulmonary fibrosisIPFantifibrotic therapypirfenidonenintedanibtreatment persistence |
| spellingShingle | Sebastian Majewski Katarzyna Górska Katarzyna B. Lewandowska Magdalena M. Martusewicz-Boros Małgorzata Sobiecka Wojciech J. Piotrowski Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland Frontiers in Pharmacology idiopathic pulmonary fibrosis IPF antifibrotic therapy pirfenidone nintedanib treatment persistence |
| title | Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland |
| title_full | Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland |
| title_fullStr | Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland |
| title_full_unstemmed | Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland |
| title_short | Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland |
| title_sort | real world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis a post hoc analysis of two multicenter observational cohort studies in poland |
| topic | idiopathic pulmonary fibrosis IPF antifibrotic therapy pirfenidone nintedanib treatment persistence |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1586197/full |
| work_keys_str_mv | AT sebastianmajewski realworldtreatmentpersistenceandpredictivefactorsfordiscontinuationofantifibrotictherapiesinpatientswithidiopathicpulmonaryfibrosisaposthocanalysisoftwomulticenterobservationalcohortstudiesinpoland AT katarzynagorska realworldtreatmentpersistenceandpredictivefactorsfordiscontinuationofantifibrotictherapiesinpatientswithidiopathicpulmonaryfibrosisaposthocanalysisoftwomulticenterobservationalcohortstudiesinpoland AT katarzynablewandowska realworldtreatmentpersistenceandpredictivefactorsfordiscontinuationofantifibrotictherapiesinpatientswithidiopathicpulmonaryfibrosisaposthocanalysisoftwomulticenterobservationalcohortstudiesinpoland AT magdalenammartusewiczboros realworldtreatmentpersistenceandpredictivefactorsfordiscontinuationofantifibrotictherapiesinpatientswithidiopathicpulmonaryfibrosisaposthocanalysisoftwomulticenterobservationalcohortstudiesinpoland AT małgorzatasobiecka realworldtreatmentpersistenceandpredictivefactorsfordiscontinuationofantifibrotictherapiesinpatientswithidiopathicpulmonaryfibrosisaposthocanalysisoftwomulticenterobservationalcohortstudiesinpoland AT wojciechjpiotrowski realworldtreatmentpersistenceandpredictivefactorsfordiscontinuationofantifibrotictherapiesinpatientswithidiopathicpulmonaryfibrosisaposthocanalysisoftwomulticenterobservationalcohortstudiesinpoland |